Tyrosine kinase inhibitors such as imatinib (marketed as Gleevec) have been developed to treat chronic myeloid leukemia (CML), in which the BCR-ABL fusion gene (the product of a reciprocal translocation between chromosome 9 and chromosome 22) is present in >95% of cases and produces hyperactivated abl-driven protein signaling.
Doctor of Medicine | Medicine | medicine | Nobel Prize in Physiology or Medicine | Physical medicine and rehabilitation | New York University School of Medicine | Baylor College of Medicine | Washington University School of Medicine | Strong Medicine | Stanford University School of Medicine | Royal Society of Medicine | Old Crow Medicine Show | Nuclear medicine | Albert Einstein College of Medicine | School of Medicine | Internal medicine | Institute of Medicine | Indiana University School of Medicine | Dr. Quinn, Medicine Woman | traditional Chinese medicine | London School of Hygiene & Tropical Medicine | Internal Medicine | Tufts University School of Medicine | Pritzker School of Medicine | Osteopathic medicine in the United States | Bachelor of Medicine, Bachelor of Surgery | alternative medicine | University of Colorado School of Medicine | New York Academy of Medicine | Veterinary medicine |